IMpower010 was a randomized, multicenter, open-label, phase 3 study done at 227 sites in 22 countries and regions.
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer in collaboration with AstraZeneca.
A new study from Memorial Sloan Kettering Cancer Center found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival. This is the first and largest randomized clinical trial ever to study the use of stereotactic body radiation therapy (SBRT) in treating oligoprogressive metastatic lung and breast cancers. These findings will be presented during this year’s American Society for Radiation Oncology (ASTRO) meeting in Chicago.
New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer.
In a new article published in JNCI Cancer Spectrum, Moffitt Cancer Center researchers describe a prediction model they have created that includes information calculated from computed tomography images that can identify non-small cell lung cancer patients who are not likely to respond to immunotherapy.
Researchers in Moffitt Cancer Center’s Lung Cancer Center of Excellence believe a combination of checkpoint inhibitors with adoptive cell therapy could be the answer for non-small cell lung cancer patients. Results of their investigator-initiated phase 1 clinical trial evaluating the checkpoint inhibitor nivolumab in combination with tumor infiltrating lymphocyte (TIL) therapy was published today in Nature Medicine.
Moffitt Cancer Center is part of a multinational, early phase clinical trial evaluating a new targeted therapy for patients with metastatic or unresectable non-small cell lung cancer who have a specific genetic mutation: EGFR Ex20Ins. New expanded data from the trial was published in the Journal of Clinical Oncology.
Results from the Phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved 12.5 months median overall survival in previously treated patients with KRAS G12C-mutated non-small cell lung cancer, according to researchers from The University of Texas MD Anderson Cancer Center.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer, according to a new study led by Yale Cancer Center researchers.
NCCN Guidelines, containing expert recommendations for cancer care, are available in French, German, Italian, Portuguese, Russian, and Spanish can all be accessed for free at NCCN.org/global or via the free Virtual Library of NCCN Guidelines® App
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being tested by Missak Haigentz, Jr., MD, medical director of hematology and oncology for Atlantic Health System. Early results appear promising in this phase 1/2 clinical trial of ADXS-503 being developed by Advaxis, Inc., a new type of cancer therapy which targets “hotspot” mutations that commonly occur in specific cancer types, both by itself and in combination with immunotherapy Keytruda® (pembrolizumab), which is commonly used to treat this type of lung cancer. Dr. Haigentz and colleagues published early results of this study in conjunction with ASCO 2020, the world’s premier scientific meeting for clinical research in oncology.
Researchers at Moffitt Cancer Center are trying to identify alternative strategies to treat non-small cell lung cancer. (NSCLC) In a new article published online in Scientific Reports, they highlight how targeting the histone deacetylase HDAC11 may be a novel therapeutic strategy for NSCLC.
Research from Rutgers Cancer Institute of New Jersey shows administering the immunotherapy drug pembrolizumab together with chemotherapy given at the same time as radiation treatment (chemoradiation) is safe and tolerable as a first-line therapy for patients with stage 3 non-small cell lung cancer (NSCLC).